Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

MSC-Derived Secretome and Exosomes in Dermatology: Mechanisms, Therapeutic Opportunities, and Scientific Challenges-A Narrative Review

da Costa Pereira Cestari M., Falavigna Tovo R., Franco Bueno D.

Clinical Trial on Skin Aging, Hair Loss, Immune Modulation, published in Int J Dermatol (2026) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Int J Dermatol (2026)
Reported sample size
—
Source database
Europe PMC
PMID
40751329
PMCID
PMC12783422
DOI
10.1111/ijd.17982
Citations
14

Abstract (original English)

Mesenchymal stromal cells (MSCs) exert their effects primarily through paracrine signaling via soluble factors and extracellular vesicles (EVs), especially exosomes. These acellular components offer regenerative and immunomodulatory benefits with fewer safety and logistical constraints than cell-based therapies. This study aims to review the composition, mechanisms of action, and dermatologic applications of MSC-derived secretomes and exosomes, including engineered and primed variants, and to discuss translational barriers and safety considerations. A structured literature search was conducted using PubMed and Embase. Studies on molecular content, preclinical and clinical data, engineered EVs, oncologic safety, and regulatory aspects of MSC-derived products in dermatology were included. The MSC secretome includes cytokines, chemokines, growth factors, lipids, and regulatory RNAs that modulate inflammation, promote repair, and support skin homeostasis. Exosomes-particularly those from primed or engineered MSCs-play a key role via targeted microRNA delivery. Preclinical data support efficacy in atopic dermatitis, psoriasis, alopecia areata, vitiligo, chronic ulcers, and photoaging. Pilot clinical trials show promising safety and feasibility for topical or intradermal use. However, product heterogeneity, unclear dosing, long-term oncologic safety, and regulatory challenges persist

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Mesenchymal Stem CellsSkinHumansSkin DiseasesMicroRNAsMesenchymal Stem Cell TransplantationDermatologyExosomesSecretome

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research